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Gan the Haemorrhagic Component
of Heparin Be ldentified?
Or an Attempt at Glean Thinking on
a Dirty Drug
Abstract
Heparin consists of different classes of molecules. We distinguish below-
critical-chain length heparin (BCLM, MW <5,400), with only anti-factor
Xa activity and above-critical-chain length material (ACLM, MW > 5,400)
with both antithrombin and anti-factorXa activity. In this article we intro-
duce a division within the ACLM fraction, between extra large material
(MW >8,000) and ACLMlow (MW 5,400-8,000). Extra large material is
abundantly present in unfractionated heparin but is rare in low-molecular-
weight (LMW) heparins. We noted that injection of an LMW heparin
causes 5- to lO-fold higher plasma levels of ACLM than injection of a
clinically equivalent dose of unfractionated heparin (UFH) and propor-
tionally higher inhibitions of the clotting system. So with LMW heparin
one can afford higher levels of anticoagulation than with UFH at a lower
risk of bleeding. We surmise that this is caused by the virtual absence of
the (haemorrhagic) extralarge-molecular-weight fraction from LMW hep-
arins. A laboratory artefact, i.e. the absence of Ca2* in the anti-factor Xa
tests, makes that heparin mixtures that lack extra large heparin molecules
show a (spuriously) high ratio of anti-factor Xa activity over anti-thrombin
activity. So the correlation between a high aXalalla ratio and a favourable
ratio ofantithrombotic effect over bleeding is not necessarily caused by the
presence of BCLM. In fact BCLM is a poor anticoagulant; in mixtures of
ACLM and BCLM, ACLM causes by far the larger part of the anticoagu-
lant effect. We surmise that the LMW fraction of ACLM is the active anti-
coagulant component in any heparin preparation and, isolated, would
make a proper third-generation heparin.
A Dirty Drug?
We may consider ourselves and our pa-
tients lucky that the classical unfractionated
heparin (UFH) was introduced and accepted
before drug regulation took its present magis-
terial proportions. Today it would not stand a
chance to pass the authorities, because it is
notoriously ill-defined and heterogeneous.
Only a limited part (30-45o/o) of all molecules
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Fig. 1 . A classif,rcation of heparin subspecies.
contain the pentasaccharide that endows the
molecule with the property to bind with high
affinity to anti-thrombin (AT) and thereby to
catalyse the interaction of that inhibitor with
clotting enzymes. This part we call the high-
affinity material (HAM) [1-3]. The remaining
low-affinity material (LAM) consists of mole-
cules that do not contribute directly and sig-
nificantly to the overall antithrombotic action
[4-6; see also below].
Low-molecular-weight heparins (LMWHs)
are prepared from UFH by reducing the mole-
cules to about one half or one third of their
original sizes. During this process, the active
pentasaccharide is sometimes cleft, which ex-
plains that LMWHs contain less HAM than
the original UFH and that the percentage of
HAM decreases with decreasing molecular
weight (MW) [7]. The decreasing MW brings
about a spectacular increase in bioavailability
after subcutaneous injection [8, 9; see also ref.
10, in which many others are cited] and pro-
duces a new fraction: heparin molecules that
do contain an intact pentasaccharide but that
are shorter than l7 monosaccharide units.
Such molecules will no longer catalyse throm-
bin inhibition but will retain their activity
towards factor Xa [1-13]. This divides
HAM in two species: ACLM, i.e. above-criti-
cal-length material, that accelerates the inhi-
bition of both thrombin and factor Xa, and
BCLM, below-critical-length material, that af-
fects factor Xa inhibition only (fig. 1).
As we will discuss below, we surmise that
essential differences exist between the ACLM
contained in LMWH and that in UFH. We
therefore want to distinguish as a separate
class those ACLM molecules that abound in
UFH but are rare in LMWHs, i.e. the higher-
MW fraction of ACLM. The boundary be-
tween the higher- and the lower-MW fraction
within ACLM is arbitrary for the moment, it
may be situated anywhere between MW 8,000
and MW 12,000. We do not even mean to sug-
gest that there are only two types of ACLM.
There may be a sharp boundary at an as yet
unknown MW, or there may be a gradual shift
in properties going from low to high MW. For
the moment, we use 8,000 as an arbitrary
boundary. Where it is necessary to make the
distinction, we will indicate the 5,400-8,000
MW fraction of ACLM as'ACLMlow'. The
hieh-Mw fraction we call extra large ACLM
(xLM) (fie. 1).
In LMWHs the 'therapeutic gap', i.e. the
range of concentrations in which the anti-
thrombotic profit outweighs the harm of the
bleeding tendency induced, is larger than in
UFH [14-16;other examples in ref. 10]. This
indicates that the properties to decrease
thrombosis and to increase bleeding are not
equally distributed over heparin fractions of
different MW.
If it would be possible to identify a subspe-
cies that carries the anticoagulant activity and
another that is responsible for the bleeding
activity, then it would be possible to identify
the better LMW heparins as those with the
maximum amount of the 'right' subspecies
and the minimum of the 'wrong' one. Even
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more interesting, identification of the 'right'
subspecies would provide a guideline to pre-
parc a superior, third-generation, heparin.
The problem is that the fractions are not
available for human or animal experimenta-
tion. UFH is a mixture of ACLM and XLM
with negligible amounts of BCLM. LMWHs
are varying mixtures of BCLM, ACLMlow
and some XLM, the composition of the mix-
ture determining its therapeutic eap ll7l.
Only idsolated BCLM is available in the form
of the synthetic AT-binding pentasaccharide
[18, 19]. A11 other heparin preparations are
mixtures; one could paraphrase Ephraim
Racker's advice 'Don't waste clean thinking
on dirty enzymes' and wait until purer hepa-
rin fractions are available. In our opinion, the
existing data already allow us to make an edu-
cated guess of what the antithrombotic- and
the haemorrhagic subspecies are.
We are aware of the fact that, probably, the
antithrombotic activity of heparin is due to
more than its AT-mediated direct anticoagu-
lant properties. Heparin e.g. causes the release
of TFPI from the vessel wall and thus pro-
vokes the appearance of another anticoagu-
lant. It may well carry still other, as yet unrec-
ognised, antithrombotic actions. Yet the anti-
coagulant effect of heparin must be consid-
ered to be its main antithrombotic property
14-61, and our discussion will be primarily in
these terms.
Glean Thinking?
When LMWH was introduced, it was ob-
served that it causes less bleeding than UFH
at the same anticoagulant activity. Also the
anti-factor Xa activity (aXa) of LMWH ap-
peared higher than that of UFH at identical
anti-thrombin activity (alla). So ahigh axal
alla ratio indicates favourable antithrombotic
properties in a heparin [see also ref. 10]. The
high aXalalla ratios were attributed to the
presence of BCLM, the species without anti-
thrombin activity. As a logical consequence, it
was thought that BCLM carries the anti-
thrombotic activity whereas the higher MW
fractions, i.e. ACLM, cause haemorrhage. On
closer observation ofthe evidence, it appears
that this conclusion is not justified. The fa-
vourable properties of a heparin appear to
reside in the LMW portion of the ACLM frac-
tion, the unfavourable ones in the XLM frac-
tion and the BCLM fraction does not carry
much weight.
In fact there is no close correlation between
aXa activity and BCLM concentration! The
high aXa/alla ratio in LMWHs is primarily
due to the fact that the lower MW fractions of
ACLM do not need Ca2* ions for the full
expression of their aXa action, whereas the
higher MW fractions (i.e. XLM) do [20]. This,
in combination with the fact that all current
aXa determinations are carried out in the
absence of Caz* ions makes that the aXa
action of XLM is systematically underesti-
mated. Because the international standard
heparin is of the XLM type, this effect causes
a spurious overestimation of the aXa activity
of ACLMlow and BCLM. A high aXalalla
ratio therefore is indicative of the absence of
XLM as much as of the presence of BCLM.
(The problem of overestimation of aXa activi-
ty in LMWHsis not solved by the adoption of
the LMWH standard; the activity of this stan-
dard is itself determined relative to the inter-
national standard in tests without Ca2* ions,
and so is itself overestimated.)
In fact, the aXa activity is a severely com-
promised indicator of heparin activity. Under
the usual laboratory conditions, it measures
all high-affrnity material, BCLM and ACLM
alike. Any given aXa activity can be caused by
an infinite number of mixtures of BCLM and
ACLM. Yet the antithrombotic properties
of these fractions are entirely different. The
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common practice to discuss heparin pharma-
cology in terms of aXa activity only [for
examples, see the overview in ref. 101 there-
fore is a hurdle to our understanding ofhepa-
rin pharmacology rather than a help.
There is an alternative though. Heparin
pharmacology should be based on the plasma
levels of the ACLM and BCLM fractions
instead of the indiscriminating aXa activity.
Indeed one can use the available anti-factor
Xa and anti-thrombin determinations to cal-
culate the levels of ACLM and BCLM that are
present in a given plasma sample [8,2I,22].
The procedure is simple. The total HAM
(= ACLM + BCLM) content can be obtained
from the aXa figure, whereas the ACLM con-
centration can be calculated from the alla
activity. The BCLM figure is then obtained by
subtraction. Once we can determine the con-
centration ofthe heparin subspecies that cir-
culte in plasma, we can determine what their
contribution is to the overall anticoagulant
effect.
It then appears that BCLM contributes
only little to the anticoagulant action of cur-
rent LMWH preparations 123-271. In an
LMWH preparation that contains both
ACLM and BCLM, it is the ACLM that car-
ries by far the larger part of the anticoagulant
action, both in vitro with the fractions added
to normal plasma and in vivo [8]. This evi-
dence will be presented in detail in the follow-
ing paragraph.
Yet, if BCLM is not the fraction that en-
dows LMWH with its favourable properties,
what fraction is? What causes the increase of
the therapeutic gap together with the increase
of the aXalalla ratio? In the paragraph to fol-
low we will show evidence that it is the lack of
the XLM fraction rather than the presence of
BCLM that makes LMWH better than UFH.
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LMWHs Are Not Likely to Act via Their
Lowest MW Fraction (BCLM)
There exists a large amount of literature on
the relative importance of alla and aXa activi-
ty for the antithrombotic action of heparins.
The scales seem to tilt slightly in favour of alla
action [0, 28] but it is clear that the outcome
depends on the thrombosis model that is used
129,30l.In the light of the discussion in the
previous paragraph one may well ask whether
the question posed in this way makes sense
and if not the more important question would
be whether the antithrombotic effect is due to
ACLM orto BCLM.
Indeed studies in which alla and aXaactiv-
ities are correlated with thrombosis scores are
extremely difhcult to interpret. There neces'
sarily is a high degree of linkage between the
two activities as such, because they are for an
important part carried by the same molecule
(ACLM) and if they are not, they are injected
together because current LMWHs are a mix-
ture of ACLM and BCLM. This high covaria-
tion makes interpretation of the outcome ex-
tremely risky. Differences in experimental ac-
curacy may also play arole. An existing corre-
lation may be blurred by random experimen-
tal error in the laboratory determinations. If
the error were larger in the antithrombin than
in the anti-factor Xa measurements then this
might show up as a difference in the signift-
cance of the correlation. Also the spurious
increase of the aXa/alla ratio in ACLMlow
molecules caused by the Ca2* effect discussed
above [20] will show up as an antithrombotic
effect of aXa activity even if ACLMlow and
not BCLM is the active molecule.
In fact there are two different questions.
One is whether aXa or aXa action per se is
antithrombotic. The other is whether ACLM
or BCLM is the antithrombotic fraction if
LMWH. The first one is easily solved by
administration of antithrombotics that affect
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one of the two clotting enzymes only. There is
no doubt that pure antithrombin action [der-
matan sulfate; 31] as well as pure anti-factor
Xa action [pentasaccharide; 18, 19] are both
antithrombotic. This probably reflects the
fact that any drug that diminishes thrombin
in clotting plasma will be antithrombotic, in-
dependent of the way in which the effect is
achieved.
The next question is whether ACLM or
BCLM is the active fraction in LMWH. On
the basis of the high aXa/alla ratio in
LMWHs, many authors jumped to the con-
clusion that BCLM must be the active mole-
cule. This thought was probably at the basis of
the efforts to try the active pentasaccharide
and its congeners as antithrombotic drugs.
Several lines ofevidence have been produced,
however, that make us believe that the role of
BCLM must be rather modest.
In vitro, heparins invariably cause an im-
portant decrease of the area under the throm-
bin generation curve [the thrombin potential;
32, 331. This can be brought about by an
increase of thrombin inactivation (as in the
case of dermatan sulfate) or by an inhibition
of prothrombin conversion [as in the case of
pentasaccharide; 261or by a combination of
both. Via a method that allows to determine
the relative contribution of both processes
1341, it could be determined that thrombin
inactivation is the more important mecha-
nism via which heparin acts 123-271. Insofar
as prothrombin activation is inhibited, this is
rather by inhibition of thrombin-mediated
feedback activation of factors V and/or VIII
than by heparin-induced inhibition of factor
Xa[23 ,21  ,35 ] .
In vitro experiments ofprothrombinase in-
hibition in flow systems on macroscopic sur-
faces corroborate this conclusion. These ex-
periments are designed to mimick the in vivo
situation in which prothrombinase (i.e. the
complex of factors Xa and Va absorbed on a
procoagulant phospholipid surface) is localised
on activated platelets adhered to a wound or a
thrombus surface. In this situation the rate of
thrombin production is determined by the rate
at which prothrombin is delivered to the sur-
face by diffusion [36]. Inhibition of prothrom-
binase is ofno consequence unless there is so
few prothrombinase left on the surface that its
capacity to convert prothrombin becomes low-
er than the velocity with which prothrombin
can arrive there by diffusion (less than about 1
per pm2, which is less than 0.10/o f the avail-
able binding sites on an activated platelet). If
that situation occurs, however, then prothrom-
binase is always maximally saturated with pro-
thrombin, and we could show that such occu-
pied complexes are immune to inhibition by
AT-heparin [37]. So AT-heparin can inhibit
those prothrombinase complexes that are not
producing thrombin anyhow, but not those
that are actively converting prothrombin into
thrombin [37] (side step for the connoisseur:
the observed K- of prothrombinase is indeed
very low, around 2mM). Preliminary results
show that some kinds of heparin, independent
of MW are more efficient inhibitors at macro-
scopic surfaces than others. Anyhow, in vitro
experiments predict that high concentrations
of aXa activity will be necessary to inhibit pro-
thrombinase effectively, so that high propor-
tions of BCLM [such as present only in certain
types of LMWH such as enoxaparin; 251
should be present if BCLM is to contribute to
the anticoagulant effect.
In vivo observations are in complete agree-
ment with these predictions. Plasma samples
obtained after injection of UFH and of enoxa-
parin and tested for their ACLM and BCLM
content as well as thrombin generation, show
that the ACLM concentration determines the
anticoagulant effect and that the contribution
of BCLM is negligible [8].
The relative unimportance of the BCLM
fraction in current LMWHs does by no means
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imply that BCLM when administered without
(or with minimal amounts of) ACLM could
not have anticoagulant and antithrombotic
properties [18, 19]. BCLM attacks factor Xa,
which is a constituent of prothrombinase. An
attack on factor Xa will in the end impede
prothrombin activation. Yin et al. [38, 39]
coined the very logical idea that it is more
effective to inhibit the thrombin-ppducing
enzyme than to remove thrombin itself. That
it is wiser to close the tap than to mop the
floor. Yet, logical as it may seem, the reason-
ing does not hold because inhibiting factor Xa
is an inefficient way to inhibit prothrom-
binase. Prothrombinase is a complex of fac-
tors Xa and Va assembled on a phospholipid
surface [40, see further ref. 41]. Its concentra-
tion depends upon the concentration of its
constituents. In clotting plasma, factor Va is
the rate-limiting component and factor Xa is
present in excess. (The plasma concentration
of factor X is around 200 nM, that of factor V
is20 nM.In the course of events that leads to
clotting, factor X is activated first and factor
V later) [see further ref. 41]. Even if factor Xa
is inhibited by 500/0, prothrombinase activity
is still hardly diminished. Inhibition of factor
Xa for 900/o inhibits prothrombin conversion
by 500/0. Compared to inhibition of thrombin
activity, inhibition of factor Xa is an ineffi-
cient means to influence the blood-clotting
process. If both aXa and alla activities are
present simultaneously, then the aXa activity
will remain in the shadow unless the ACLM
content becomes very low. If only the aXa
activity is there, as in the synthetic AT-bind-
ing pentasaccharides, then of course thrombin
generation can be inhibited via the inhibition
of prothrombinase [26].
Those that want to obtain anticoagulant
action via the inhibition of prothrombin con-
version (i.e. by anti-factor Xa activity) will
therefore probably have to go to relatively
high inhibitions of factor Xa.
In summary: on a molar basis, ACLM is a
tenfold more effective anticoagulant than
BCLM is. Only if the BCLM molecules out-
number the ACLM by a factor of ten or more,
will the BCLM contribute significantly to the
overall anticoagulant effect in plasma. In prac-
tice the admixture of BCLM to ACLM will
hardly contribute to the anticoagulant proper-
ties of the latter. The admixture of BCLM to
ACLM aswe observe it in the current, clinically
used LMWH preparations will not or hardly
contribute to anticoagulant action, but it does
contribute to the aXa activity and so is respon-
sible formuch ofthe confusion that exists in the
laboratory assessment of heparin activity.
LMWHs Are Likely to Lack a
Haemorrhagic Gomponent Present in
Unfractionated Heparin
If the difference between LMWH and
UFH is not likely to reside in the presence of
the BCLM fraction, then it must reside in the
ACLM fraction. Indeed there are large differ-
ences in the pharmacokinetics of the ACLM
from LMWH and from UFH. We found that
the bioavailability of the ACLM fraction of a
LMWH after subcutaneous injection is 6-8
times higher than that of UFH [8]. This find-
ing is backed up by alarge number of studies
in which the bioavailability of LMWHs and
of UFH has been compared without making
the distinction between ACLM and BCLM
[see ref. 10 for a review]. What can be the
cause of this shift in bioavailability with the
MW distribution? One possibility is that only
ACLMlow is found back in the blood stream
and that XLM does not appear at all. The low
bioavailability of UFH, would then reflect its
low proportion of ACLMlow. This is corrob-
orated by the finding ofan identical apparent
pharmacological halfJife time for the ACLM
after subcutaneous injection of either LMWH
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or UFH [8]. It is well known that the halfJife
time of a heparin varies strongly with the
molecular size [10, 42]. Identical halflife
times suggest hat the MW distribution of the
ACLM in the blood after injection of UFH is
similar to that after injection of LMWH.
If indeed only ACLMlow is the bioavail-
able species and if XLM is not to be found in
the blood stream, this might be explained in
two ways: either XLM does not travel from
the injection site to the blood stream or XLM
disappears so quickly from the blood that it is
never observed. It is quite conceivable that it
sticks to the vessel wall immediately [43] and
in this way affects hemostasis locally.
One might consider to administer UFH in
doses that are seven times higher than the
usual ones (e.g. 35,000 IU twice daily) so as to
obtain the same plasma levels of ACLM as in
a prophylactic regimen with a LMWH. With-
out any doubt, judging from clinical experi-
ence, this would cause a sizeable increase of
the bleeding frequency. So, although the
amount of anticoagulant material in the blood
stream would be the same, the bleeding risk
would be much increased. This suggests that
there is haemorrhagic material contained in
UFH but not (or much less) in LMWH. The
obvious candidate is XLM and/or the LAM
fraction of the same size.
From the above we surmise that in any cur-
rent heparin preparation, the ACLM-low frac-
tion, i.e. the high affinity fraction of between
5,400 and 8,000 MW, is the one that brings
about anticoagulation at a low bleeding risk.
Fractions with a MW <5,400, as discussed
above, are not likely to be the active compo-
nent in current LMWHs. Fractions above a
certain limit (i.e. XLM) may not reach the
blood stream or disappear very fast, and prob-
ably have haemorrhagic properties.
Again we stress that 8,000 as a lower MW
boundary for XLM is arbitrary. It has not
been determined experimentally. Its actual
value can be determined by measuring the
MW distribution of the heparin fractions that
circulate after subcutaneous iniection of UFH
or LMWH.
The ACLM-low fraction makes a good can-
didate for the ideal heparin. It will in all prob-
ability combine a high anticoagulant potency
(and therefore a low IC5e in venous thrombo-
sis models) with reliable and high bioavail-
ability at minimal haemorrhagic risk. Unlike
with UFH, the haemorrhagic complications
will probably be related to the degree of anti-
coagulation obtained. The plasma levels of
this material will be easy to determine via its
aXa activity but, contrary to the present
LMWHs that contain BCLM, the outcome
will be readily interpretable. In essence, this
material is good old UFH with a high bio-
availability and without the high-MW mole-
cules that are likely to cause haemorrhage.
A drawback of this fraction might be that,
unlike BCLM, it is neutralised by heparin-
binding material from activated platelets. Re-
cent work from the group ofBoneu [29, 30] has
shown that (in rabbits) in venous models the
antithrombotic activity seems to correlate with
the AT activity of the material injected, where-
as in arterial models the aXa activity seems to
gain in importance. Although the data have to
be interpreted with caution (see above), this
reminds us that thrombosis is sufficiently di-
verse to need a diverse therapeutic approach.
The above-defined heparin fraction is there-
fore not necessarily optimal for both venous
and arterial thrombosis. It is an educated guess
that it will be the useful heparin for the pre-
vention of venous thrombosis. It will be neu-
tralised, however, by platelet factor 4 from
activated platelets. BCLM is not, or much less,
so one can imagine that a pure BCLM fraction
is the drug of choice in the prevention of
growth of arterial thrombi 144,451.
It seems that at this moment a pure BCLM
is being developed for clinical usage. It is our
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guess that ACLMJow without BCLM and
without XLM is at least as interesting a prod-
uct and merits to be prepared and tested in a
clinical trial.
What Use ls the LAM?
It has been demonstrated that the LAM
fraction in itself does not have significant ani-
thrombotic properties but that it can enhance
the antithrombotic properties of HAM [4-6].
One can imagine the following mechanisms:
(a) LAM has AT activity via its action on hep-
arin cofactor II [46]. For this action to be sig-
nihcant, concentrations ofheparin are needed
that are 10-20 x higlrer than those generally
used, so this effect will be negligible in prac-
ticel47l. (b) LAM may release TFPI from the
vessel wall. If TFPI is washed from the vessel
wall by a mechanism that is independent of
AT-binding then LAM and HAM of equal
size and charge will not differ in this respect.
The contribution to the antithrombotic effect
is unknown. (c) LAM will displace HAM from
non-specific binding sites on cells and plasma
proteins, in this way setting active heparin
molecules free for their specific interaction
with AT 148,491. This phenomenon is respon-
sible for the fact that in plasma heparin action
is proportional to AT concentration, even
though AT is present in excess over the con-
centration of heparin, so that one might think
that all heparin would be bound to AT (to give
an approximative idea of the molar concen-
trations involved: a plasma concentration of
1 IU/ml of UFH represents about 5 pglml of
crude material,35o/o of which is HAM. At an
assumed MW of around 10,000, this repre-
sents 0.1-0.2 1tM of active material. AT III is
present at a concentration of 2-3 pM).
None of these functions of LAM has been
shown to be essential for the anticoagulant
action of heparin in patients, although they
may contribute to it. On the other hand, a
contribution of LAM to the bleeding effect
has been observed [50].
It is logical to think that antigenic- and
toxic effects are a function ofspecific oligosac-
charide sequences within the heparin mole-
cule, which will automatically be more abun-
dant in higher-molecular-weight heparins. We
conclude that, as far as we can reason, LAM
does not carry a known useful function, that it
may contribute to undesired side effects of
heparin and that larger LAM molecules will
be worse in this respect than smaller ones.
Retrospective and Future
In retrospect, those who claimed that a
high aXa activity makes a good heparin were
right, be it for reasons that they did not sus-
pect. It is not because the molecules without
AT activity (BCLM), have particular$ good
properties but, more probably than not, be-
cause the ACLMlow fraction, which by fa-
vour of its high anticoagulant activity, its high
bioavailability and long half-life time is the
better component of heparin, is also the frac-
tion that is overestimated in the usual aXa-
tests. The XLM fraction, that is likely to cause
bleeding, is not overestimated.
Of course the hypotheses forwarded here
require more experimental backup. A relative-
ly simple but revolutionary experiment would
be to isolate XLM and show that it is an inef-
ficient antithrombotic that causes bleeding.
This expected outcome would make further
use of UFH rather questionable. A more schol-
arly approach would be to determine the MW
distribution of heparin fractions found in cir-
culation after subcutaneous injection of UFH.
Anyhow it is clear from the present consider-
ations that the presently available LMWHs are
a step forward compared to UFH but may still
be improved considerably.
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